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Summary
Setting: Multi-drug TB resistant (resistant to isoniazid and rifampicin) patients identified from a rural and urban area.
Objective: To study the feasibility of managing MDR TB patients under field conditions where DOTS programme has been
implemented
Methods: MDR TB Patients identified among patients treated under DOTS in the rural area and from cases referred by the
NGO when MDR TB was suspected form the study population. Culture and drug susceptibility testing were done at Tuberculosis
Research Centre (TRC). Treatment regimen was decided on individual basis.  After a period of initial hospitalization, treatment
was continued in the respective peripheral health facility or with the NGO after identifying a DOT provider in the field.
Patients attended TRC at monthly intervals for clinical, sociological and bacteriological evaluations. Drugs for the month were
pre-packed and handed over to the respective center.
Results: A total of 66 MDR TB patients (46 from the rural and 20 from the NGO) started on treatment form the study
population and among them 20 (30%) were resistant to one or more second line drugs (Eto, Ofx, Km) including a   case of
“XDR TB”. Less than half the patients stayed in the hospital for more than 10 days. The treatment was provided partially
under supervision. Providing injection was identified to be a major problem. Response to treatment could be correctly predicted
based on the 6-month smear results in 40 of 42 regular patients. Successful treatment outcome was observed only in 37% of
cases with a high default of 24%. Adverse reactions necessitating modification of treatment was required only for three
patients.
Implications Despite having reliable DST and drug logistics, the main challenge was to maintain patients on such prolonged
treatment by identifying a provider closer to the patient who can also give injection, have social skills and manage of minor
adverse reactions.
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INTRODUCTION
One of the major threats to TB control is
the emergence of drug resistant TB, particularly multi-
drug resistant TB (MDR TB) – TB strains resistant
to Isoniazid and Rifampicin. Of the 424,203 MDR-
TB cases estimated world-wide by the WHO, more
than half the cases are estimated to be in China and
India1. Identifying this problem, the Revised National
Tuberculosis Control Programme (RNTCP) in India,
is planning to introduce DOTS-Plus services into
the programme for the management of MDR-TB
patients. There are several reports on the
management of MDR-TB in the field,2-9 but limited
information is available from India.
The Tuberculosis Research Centre (TRC),
Chennai has been monitoring the RNTCP DOTS
programme in a rural area 10 and giving technical
support to an NGO implementing RNTCP in the city
of Chennai in the southern part of India. As a part of
operational research activities, TRC, with its well
established myco-bacteriology laboratory, recognised
as a National Reference Laboratory of RNTCP and
as a Supra-national Reference Laboratory of the
WHO, has been monitoring drug susceptibility profile
(DST) of all patients registered for treatment in the
rural area and for chronic cases referred by the NGO.
DST included both first and second line drugs.
Patients identified to have MDR TB were referred to
TRC for further management. This paper describes
the experience of management of MDR-TB patients
under field conditions and also our observations on
extensively drug-resistant TB ( XDR-TB, see
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footnote1) in this group of patients.
MATERIAL  AND METHODS
Setting
The study area is a sub-district
(predominantly rural) of Tiruvallur district, in south
India, with population of 580,000 where RNTCP was
implemented in May 1999 and TRC was monitoring
the DOTS programme. The area has 17 governmental
health care facilities, including 7 designated
microscopy centers. From this study area, during
1999-2003, 4467 patients were registered and among
them 2206 had positive cultures. Of these 81 were
identified as MDR-TB and 48 initiated on treatment.
One patient had XDR pretreatment.
A non-governmental organization working
in Chennai city involving the private sector to support
RNTCP also referred. 35 patients of suspected to
have MDR-TB and 20 were initiated on treatment.
Study population
MDR-TB patients identified from the two
areas and referred to TRC for management during
May 1999 to December 2003 form the study
population.
Pre-treatment Investigations
Procedures for sputum culture and drug
susceptibility testing
For all tuberculosis patients registered for
treatment under RNTCP in the rural area, two
additional sputum samples were collected within one
week of starting treatment, if a patient became
smear-positive during treatment, and at 12, 18 and
24 months from all cured patients as an operational
research activity. The NGO in Chennai city referred
patients with suspected MDR TB and two sputum
specimens were collected at TRC. All specimens
were processed at TRC for culture and drug
susceptibility testing. Sputa were collected in sterile
McCartney bottles containing cetyl pyridinium
chloride (CPC) 11 provided by TRC. If missed, TRC
field staff visited the patients’ homes and collected
sputa within a week. Sputum was also collected at
12, 18 and 24 months by TRC field staff as part of
an operational study to assess relapse12. All specimens
were subjected to culture for M.tuberculosis and drug
susceptibility testing for Isoniazid (H), Rifampicin
(R) and  Streptomycin (S) on Lowenstein Jensen
medium (LJ medium)13. Concentrations of H, R and
S used were 0.2, 1, 5; 32, 64, 128; and 8, 16, 32, 64
mg per litre respectively. The resistance to H and R
was determined by minimal inhibitory concentration
(MIC) and to S by Resistance Ratio (RR) methods14.
MIC of 1mg/litre or more and MIC of 128mg/litre
or more, were defined as resistance for H and R
respectively and an RR of 8 or more was considered
as resistance to S15. DST was done for Kanamycin
(K), Ethionamide and Ofloxacin at the time of starting
treatment for MDR-TB by MIC methods. The
concentrations of Ofloxacin used were 2, 4, 8 for
Kanamycin 8, 16, 32 & 64 and Ethionamide as 20,
28, 40, 57, 80 and 114. MIC of and of >8 for
Ofloxacin, >64 for Kanamycin and >114 for
Ethionamide were considered as resistance. DST to
second line drugs was done based on the drugs
patients were treated with.
Other investigations
Patients identified to have MDR-TB
were referred to TRC, Chennai for further
management. Prior to starting treatment all
pa t ients  underwent  de ta i led  c l in ica l ,
sociological and bacteriological evaluations. In
addition, chest radiograph, hepatic and renal
function tests and complete haemogram were
done.  HIV tes t ing was  done af te r initial
counseling and obtaining informed consent.
Treatment regimen
Patients were started on treatment on an
individual basis, primarily based on the drug
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susceptibility profile. The regimens used were:
Group I: 6Sm3 / Km3 Ofx Eto Z E daily followed
by 12 Ofx Eto Z E daily
Group II: Other combinations for eg.
6Sm3 / Km3 Ofx Eto Z H high dose daily followed
by 12 Ofx Eto Z H daily
6Sm3 / Km3 Ofx Z E with Cs/PAS/High dose
INH daily followed by 12 months of oral drugs
etc.
Drugs and dosage:
Streptomycin (Sm)    0.75 gm thrice a week
Kanamycin (Km)       1.00 gm thrice a week
Ofloxacin  (Ofx)        400–600 mg daily
Ethionamide (Eto)      500 mg daily
Ethambutol (E)          800 mg daily
Pyrazinamide(Z)        1.5 gm daily
PAS                         10 gm daily
Cycloserine (Cs)        500mg daily
Amikacin (Am)          1 gm daily
 Isoniazid (INH)         600mg daily
Duration of treatment
Patients received all the five drugs for the
initial 6-month period. During the next 12 months
the injection was stopped and treatment continued
with oral drugs. The total duration of treatment was
for a minimum period of 18 months or 12 months
after the culture negativity whichever came later.
Patient management
After initiation of treatment, the patients were
advised hospitalization in one of the TB hospitals in
Chennai city for a minimum period of one month to
monitor the drug tolerance. On discharge from the
hospital, clinical, bacteriological and sociological
assessments were done at TRC and patients were
advised to attend the respective Primary Health
Centre (PHC) / NGO for continuation of treatment.
Drugs for one week were supplied to the patient to
ensure continuity of treatment during the transit
period. The patients were transferred to the PHC
Medical Officers / NGO for continuation of
treatment. Details of the chemotherapy prescribed
and dates for further assessment were intimated
through a referral letter. A DOT provider was
identified for administering drugs under direct
observation. These providers were given on the spot
training for drug administration and adverse reactions
to be anticipated and the action to be taken. Patients
received the treatment under partial supervision i.e.
thrice-a-week when patients attended for injection,
oral drugs were given under supervision and the next
day’s dose was supplied for self administration. The
same procedure was followed after the injection
phase was completed.
Clinical assessment and sociological
counseling were done every month at TRC.
Reminders were sent to the patients one week prior
to the due date for monthly checkup. During these
monthly follow-ups, an early morning and spot
sputum specimens were examined by smear and
culture for M. tuberculosis. For all patients financial
assistance to compensate for the loss of wages and
travel expenses on the day of attendance to TRC
was given.
Drug Logistics
Drugs were provided by TRC as there was
no provision for second line drugs in the field. During
the period of hospitalization, TRC health worker
supplied the drugs to the hospital staff on alternate
days. After discharge, patients continued treatment
at their respective PHCs/private providers or TRC
clinic where they received the drugs from a DOT
provider. Pre-packed drugs (each dose in a separate
packet) were supplied to the respective PHC/NGO
on a monthly basis, following the patient’s monthly
follow-up visit at TRC. Patients attended on alternate
days to receive the drugs under observation and the
next days drugs were supplied for self-administration
i.e. treatment was given under partial DOT.
Definitions of treatment outcomes
Cured: A patient who has completed treatment
for at least 18-months and has been culture
negative for the final 12 consecutive months of
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treatment.
Death: A patient who dies during the course of
treatment.
Failure: A patient who remains culture-positive at 6
months or those who become consistently positive
subsequently during treatment and require change
of treatment.
Default: A patient who had interrupted treatment
for two or more consecutive months.
RESULTS
In all 68 (48 from the Tiruvallur area and
20 from Chennai city) patients were started on
treatment for MDR-TB. Of the 48 patients started
on second line drugs from Tiruvallur area, 2 patients
were subsequently excluded (one patient had
organisms sensitive to Rifampicin and other negative
culture at the time of initiation of treatment for MDR-
TB) – hence analyses was done on 66 MDR-TB
patients.
The demographic profile of patients is
described in Table 1. Of 66 patients, 70% were
males; the mean age was 38 years (range 14-75)
and mean weight was 42.7 kg (range 23.2–60.5).
Of the 66 patients, 7 had received less than 6-months
of prior treatment, 27 6-9 months, and 32 more than
9 months. All patients had received treatment with
either CAT-II and/or CAT-I regimen under RNTCP.
Drug sensitivity pattern
At the start of treatment twelve (18%)
patients had organism resistant only  to HR, 34 (52%)
resistant to one or two of the first line drugs in
addition to HR (S/E), and the remaining 20 (30%)
were resistant to one or more second line drugs (Eto,
Ofx,  Km) in addition to HR (Table 2). Of 33 patients
for whom DST results for  Km and Ofx are available,
one had organism resistant to both Km and Ofx in
addition to HR, i.e. was a case of extensive drug
resistant TB – “XDR-TB”.
Patient management
Of the 66 patients, 30 were not admitted to
the hospital and another 10 stayed in the hospital for
less than 10 days. The main reasons were: not able
to stay away from work and the distance to the
hospital from their residence. In the rural area the
DOT provider identified was mainly anganwadi
workers. Patients received injections either from the
village health worker whenever available or from a
private provider by paying or went to the primary
Table 1: Demographic profile of patients on
treatment for MDR TB
Table 2. Drug susceptibility profile at the time
of initiation of MDR-TB treatment
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health center. The urban patients took treatment either
at TRC clinic or from the nearby private hospital or
a practitioner involved in the RNTCP.
Treatment outcome
Of the 66 patients, 25 (38%) patients were
‘cured’, 17 (26 %) failed, 16 (24%) defaulted and 8
(12 %) died during treatment (Table 3).  The outcome
with respect to regimens I (46 patients) and II 20
patients) were: cure 19 (41%) vs 6 (30%), failure
14 (30%) vs 3 (15%), default 10 (22%) vs 6 (30%),
death 3 (7%) vs 5 (25%) (Table 4). The difference
in cure was not statistically significant. Treatment
outcome was not related the duration of prior
chemotherapy received.
Treatment outcome related to resistance pattern
Among the 12 patients with HR resistance,
5 were cured, 2 failed, 4 defaulted and 1 died (Table
3). Among the 34 patients with resistance to HR +
S/E, 12 (35%) cured, 9 (26%) failed, 8 (24%)
defaulted and 5 (15%) died. Of the 20 patients who
had resistance to second line drugs in addition to
HR, 8 (40%) were cured, 6 (30%) failed, 4 (20%)
defaulted and 2 (10%) died. These differences were
not statistically significant.
Culture conversion among cured patients
Among 25 patients cured, culture
conversion occurred at first month for 8 (40%), at
2 months for 6 (30%), 3 months for 2 (10%), at 4
months 2 (10%) and 1 (5%) patient each at 5 and 9
months.  Overall 14 (70%) converted by 2 months
and 18 (90%) converted by 4 months. All except
two cured patients had smear conversion also by 3rd
month and all failures were smear-positive at 3rd
month.
Status of defaulters and failures
Of the 16 patients who had defaulted, treatment was
resumed for eight patients, three had died and the
remaining five continued to default. Default was
attributed to be due to adverse drug reactions by
four patients. Among 17 failures, 2 died. Treatment
was changed for the remaining 15 patients, two
patients defaulted and of the remaining 13 patients,
five patients are responding to the new treatment.
One patient who was resistant to SmHRKmEEto
emerged resistance to Ofx and another patient who
had resistance to SmHREEto emerged resistance to
Km and Ofx i.e. 2 patients developed  XDR-TB
resistance during treatment.
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Table 3: Treatment outcome of the MDR TB patients according to the resistance pattern
Table 4: Treatment outcome of the MDR TB patients according to the treatment regimens
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Regimen No. of  pts Cured   (%) Failure   (%) Default   (%) Death   (%) 
Tiruvallur area 46    19     ( 41.3)     14       (30.4)      10        (21.7)    3        (6.6) 
Chennai city 20      6     (30.0)        3       (15.0)        6        (30.0)    5      (25.0) 
Total Pts 66    25     (37.8)     17       (25.0)      16        (24.3)    8      (12.2) 
 
 
Resistant to No. of  
patients 
Cured    (%) Failure   (%) 
 
Default    (%) Death    (%) 
HR 12      5      (41.6)      2        (16.7)      4          (33.4)     1        ( 8.3) 
SHR/HER/SHRE 34    12      (35.3)      9        (26.5)      8          (23.5)     5       (14.7) 
HR + other Drug(s) 20      8      (40.0)      6        (30.0)      4          (20.0)     2       (10.7) 
Total  patients 66    25      (37.8)    17        (25.7)    16          (24.3)     8       (12.2) 
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Sputum status at 6 months
All the 25 patients with negative smears for
AFB at 6-months of treatment had a favourable
response (cure) Among the 17 failures, 16 were
smear-positive at 6-months.
Adverse drug reaction
Of the 66 patients, 39 (59%) had adverse
reactions, among these 26 (67%) gastrointestinal, 7
(18%) skin, 5 (13%) giddiness, 3 (8%) had insomnia
and only one patient had jaundice. However
Ethionamide had to be withheld in only one patient
and two patients were managed by changing to
enteric coated Ethionamide tablets. All drugs were
withheld for three weeks for the patient who
developed jaundice, and treatment was reintroduced
and continued without any further problem.
DISCUSSION
The main finding of our study was that of
the 66 MDR TB patients treated cure was observed
only amongst 38%, despite ensuring quality
diagnosis and drugs. Default of 24% and failure of
26% were observed. The response was not
influenced by resistance pattern or the treatment
regimen or duration of treatment prior to MDR-TB.
This study was an attempt to investigate
the feasibility of managing MDR TB patients in
the field including the diagnosis, drug logistics,
ensuring DOT with injection, ensuring compliance
and management of adverse reactions. The
problems faced included difficulty in initial
hospitalisaton, identifying a motivated provider
residing closer to the patient who can give
injections and motivate the patient to continue 18-
months of treatment. In our series less than half
the patients were hospitalized or stayed for more
than 10 days in the hospital. This was probably
due to the fact that the hospital was at least 50km
away from their homes and patients were not able
to stay away from the work. The prolonged
nature of treatment, apart from innumerable visits
for drug intake includes periodic visits to the nodal
center for clinical and laboratory evaluations.
Financial assistance was given when patients
attended the nodal centre.
One of the major problems encountered in
the field was finding a DOT provider who could
give intramuscular injection to the patients. Rural
patients received their injections from the village heath
worker whenever they were available at the sub-
center and on other occasions either from a private
provider by paying a fee or from the primary health
center. Patients from the urban area either attended
TRC outpatient clinic or took treatment from their
referral hospital/practitioner. All efforts should be
taken before starting treatment to identify a DOT
provider nearer to the patient’s residence, who could
administer injections, possibly  by involving net work
of private providers available in most villages.
Drugs were supplied from TRC, Chennai
as there was no established treatment strategy for
MDR-TB patients in the study area at that time.
Packing of drugs, transporting to the field, handing
it over to the DOT provider and ultimately to the
patient required constant supervision and monitoring
at every step.
The poor cure rate observed (36%) in the
current study, is similar to another report from our
centre, where only 31% of 105 patients treated with
S/KmEtoZE and 47% of 30 treated with salvage
regimen containing OfxH600 and 2-4 drugs from
Am/Eto/T/Z were cured16. Similarly a study done
from Denver in 1993, reported a successful
treatment outcome of 56%, despite a median stay
for more than 7 months in the hospital. Similarly
studies from USA, Argentina, and Peru have reported
favourable outcomes of around 45%2-4. The
unsuccessful response to therapy prescribed in these
series was strongly associated with greater number
of drugs received previously and male sex2 and
resistance to more than 5 drugs2-4. A recent report
from India had shown 68% cure among 28 patients
who had completed 24 months of treatment
schedule5. On the other hand, studies done at Korea,
Vietnam, Netherlands and Turkey had shown
favourable treatment outcome above 75%6-9. The
reason for good response in the New York group
was attributed to the fact that majority (68%) of
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their patients had not given history of anti-
tuberculosis treatment earlier. In the Korean study
response was assessed excluding patients who were
discharged prematurely and those who had additional
intervention. It was contrary to the current series,
where all patients had received varying duration of
anti-tuberculosis treatment with 4 or 5 drugs. The
poor success rate was observed mainly due to the
high default (24%) and failure (26%) rates. The
supply of ATT under partial DOTS may also be one
of the factors responsible for the poor outcome.
Promising results have come from the independent
study from Lativa and the combined outcome of 5
DOTS Plus sites showing success rate of 66% and
70% 1,17.
Recently, there have been a number of
reports on XDR TB. There is global concern over
the emergence of XDR-TB which leaves patient
virtually untreatable using currently available anti-
TB drugs.  WHO and CDC on data from 2000-2004
found that XDR has been identified in all regions of
the world but is most frequent in countries of former
Soviet Union and in Asia. Four percent of MDR from
USA, 19% from Latvia met the criteria of XDR18. In
our series one patient had XDR TB at the start of
treatment. Of 33 MDR TB patients treated with
regimens containing Km and Ofx, two had
emergence of XDR TB. To our knowledge this is
the first report on the existence of XDR TB from
India.
Response to treatment could be correctly
predicted based on the 6-month smear results
in 40 of 42 patients. Thus 6-month smear status
can be used as a surrogate marker for response
to treatment and those who remain positive at
6-months can be considered for change of
treatment.
Implications for the programme
India is currently planning to implement
DOTS Plus in two sites. There is a need to ensure
reliable DST, prompt and regular delivery of
drugs to the PHC, identifying a provider for
prolonged DOT who can give injection and who
has the  social skills to maintain patients on such
a prolonged treatment with repeated motivation
and ability to management of minor adverse
reactions.
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